Corcept Therapeutics

Last updated

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. [1] Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. [2] Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. [3]

Contents

Corcept Therapeutics Inc.
Company type Public
IndustryPharmaceutical Industry
FoundedMay 13, 1998;25 years ago (1998-05-13) [4]
Headquarters
Menlo Park, California
Key people
Joseph K. Belanoff (CEO, president, & director)
ProductsPharmaceutics
Website www.corcept.com

History

Backed by Silicon Valley biotech investors, [5] Corcept Therapeutics was founded in May 1998 [6] by psychiatrists Alan Schatzberg and Joseph K. Belanoff. Eight years later, Corcept remained a small firm with 11 full-time employees. Much of its work (e.g., drug manufacturing and testing on patients) was farmed out to others. [5]

In June 2008, U.S. Senator Chuck Grassley, then the ranking Republican on the Senate Finance Committee, criticized Corcept cofounder and prominent psychiatrist Alan Schatzberg, chair of the psychiatry department at Stanford University School of Medicine, for not fully informing the university about the value of his shares in Corcept. According to Grassley, Schatzberg had reported stock holdings in Corcept worth "over $100,000," when, in fact, the psychiatrist's stake exceeded $6 million. [7] In July, Stanford said that Schatzberg "appropriately disclosed any potential financial conflict of interest," but announced he would nevertheless step down temporarily as principal investigator on his National Institute of Mental Health grant to study the effectiveness of the abortion drug mifepristone as an antidepressant. Grassley also asked Stanford to explain its own financial ties with Corcept, saying the university held licensing agreements for mifepristone. [8] The National Institutes of Health later reinstated Schatzberg as principal investigator. [9]

Treatments

Prolonged exposure to cortisol can lead to a wide range of sometimes life-threatening conditions, including Cushing's syndrome, antipsychotic drug-induced weight gain, diabetes, obesity, hypertension, Alzheimer's disease, posttraumatic stress disorder, alcoholism, prostate, breast and ovarian cancer. [2] Corcept Therapeutics has developed over 300 proprietary molecules, which it investigates in collaboration with outside researchers to determine if they can mitigate the effects of excess cortisol. [2]

Korlym

In 2012, Corcept launched the prescription medicine Korlym, a cortisol receptor blocker to control hyperglycemia (high blood sugar) in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery. [10] Korlym was the first FDA-approved oral therapy for the treatment of such patients. [11] Since Korlym was an orphan drug—i.e., one developed specifically to treat a rare medical condition—Corcept received seven years of exclusive marketing rights, as well as tax credits for clinical trial costs, marketing application filing fee waivers, and assistance from the FDA in the drug development process. [12] In 2013, Corcept reported $19.7 million in federal tax credits. [13] Corcept's marketing exclusivity for Korlym will end on February 17, 2019, at which time competitors could attempt to introduce generic equivalents. [12] As of 2018, Korlym is Corcept's only product and treats about 1,000 patients annually in the U.S. [13]

Korlym's active ingredient is mifepristone, also known as RU-486, which is a medication typically used in combination with misoprostol to bring about an abortion. [14] Developed in France in 1980, [15] mifepristone was approved by the FDA in 2000 for abortion in the U.S. [16] Since then, [13] mifepristone has been marketed by Danco Laboratories, a private pharmaceutical distributor, under the brand name Mifeprex, and is Danco's only product. [17]

In 2018, Kaiser Health News reported that the difference in price between Danco's Mifeprex and Corcept's Korlym "is striking, even though the ingredients are the same: One 200-milligram pill to prompt an abortion costs about $80. In contrast, a 300-milligram pill prescribed for Cushing's runs about $550 before discounts. Patients wanting an abortion take only one pill. People with Cushing's often take up to three pills a day for months or years." [13] While the price of Mifeprex has remained stable, the price for Korlym has increased nearly 150 percent over the past six years, rising to an average yearly cost per patient of $180,000. [13] "We have an expensive drug," said Corcept's CEO Joseph K. Belanoff, MD. [3] "There's no getting around that." [13]

In 2017, Corcept's revenue nearly doubled to $159.2 million, and executives expect to reach $275 million to $300 million in 2018. In January 2018, Corcept's stock price rose 27.4 percent. Executives say revenue from Korlym, which cost about $300 million to develop, has paid for development of new drugs. By December 2016, Corcept had discovered three structurally distinct series of selective cortisol modulators that, unlike mifepristone, do not terminate pregnancy. [4] In March 2018, Corcept reported an encouraging phase II clinical trial update on relacorilant, a possible successor to Korlym that could treat Cushing's syndrome without the side effects of endometrial thickening and vaginal bleeding experienced by some women. [13]

Warning. Since each tablet for oral use contains 300 mg of mifepristone, [18] Korlym should never be taken by women who are pregnant or who might become pregnant. Taking Korlym during pregnancy will result in the loss of a pregnancy. [19]

Oncology

In December 2013, the company announced plans to extend its development program for glucocorticoid receptor (GR) antagonists into oncology, and licensed patent rights from the University of Chicago's Center for Technology Development & Ventures covering the use of GR antagonists in combination with chemotherapy in the treatment of breast cancer. [1]

Related Research Articles

<span class="mw-page-title-main">Emergency contraception</span> Birth control measures taken after sexual intercourse

Emergency contraception (EC) is a birth control measure, used after sexual intercourse to prevent pregnancy.

<span class="mw-page-title-main">Cushing's syndrome</span> Symptoms from excessive exposure to glucocorticoids such as cortisol

Cushing's syndrome is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. Signs and symptoms may include high blood pressure, abdominal obesity but with thin arms and legs, reddish stretch marks, a round red face due to facial plethora, a fat lump between the shoulders, weak muscles, weak bones, acne, and fragile skin that heals poorly. Women may have more hair and irregular menstruation. Occasionally there may be changes in mood, headaches, and a chronic feeling of tiredness.

The American Psychiatric Association (APA) is the main professional organization of psychiatrists and trainee psychiatrists in the United States, and the largest psychiatric organization in the world. It has more than 38,000 members who are involved in psychiatric practice, research, and academia representing a diverse population of patients in more than 100 countries. The association publishes various journals and pamphlets, as well as the Diagnostic and Statistical Manual of Mental Disorders (DSM). The DSM codifies psychiatric conditions and is used mostly in the United States as a guide for diagnosing mental disorders.

<span class="mw-page-title-main">Mifepristone</span> Medication

Mifepristone, also known as RU-486, is a medication typically used in combination with misoprostol to bring about a medical abortion during pregnancy and manage early miscarriage. This combination is 97% effective during the first 63 days of pregnancy. It is also effective in the second trimester of pregnancy. It is taken by mouth.

Walgreens is an American company that operates the second-largest pharmacy store chain in the United States, behind CVS Health. It specializes in filling prescriptions, health and wellness products, health information, and photo services. It was founded in Chicago in 1901, and is headquartered in the Chicago suburb of Deerfield, Illinois. On December 31, 2014, Walgreens and Switzerland-based Alliance Boots merged to form a new holding company, Walgreens Boots Alliance. Walgreens became a subsidiary of the new company, which retained its Deerfield headquarters and trades on the Nasdaq under the symbol WBA. In 2021 the company was found by a federal jury to have "substantially contributed to" the opioid crisis.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Gedeon Richter (company)</span> Hungarian pharmaceutical company

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection. It works by inactivating tumor necrosis factor-alpha (TNFα).

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

<span class="mw-page-title-main">Roussel Uclaf</span> French pharmaceutical company

Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.

Danco Laboratories is a pharmaceutical distributor located in midtown Manhattan which distributes the abortifacient drug mifepristone under the brand name Mifeprex. Mifeprex is the only drug distributed by Danco, although the company plans to expand to other drugs in the future.

<span class="mw-page-title-main">Ulipristal acetate</span> Chemical compound

Ulipristal acetate, sold under the brand name Ella among others, is a medication used for emergency contraception and uterine fibroids. As emergency contraception it should be used within 120 hours of vaginally penetrating intercourse. For fibroids it may be taken for up to six months. It is taken by mouth.

<span class="mw-page-title-main">Acorda Therapeutics</span> American biotechnology company

Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.

<span class="mw-page-title-main">Birth control in the United States</span> History of birth control in the United States

Birth control in the United States is available in many forms. Some of the forms available at drugstores and some retail stores are male condoms, female condoms, sponges, spermicides, and over-the-counter emergency contraception. Forms available at pharmacies with a doctor's prescription or at doctor's offices are oral contraceptive pills, patches, vaginal rings, diaphragms, shots/injections, cervical caps, implantable rods, and intrauterine devices (IUDs). Sterilization procedures, including tubal ligations and vasectomies, are also performed.

A medical abortion, also known as medication abortion or non-surgical abortion, occurs when drugs (medication) are used to bring about an abortion. Medical abortions are an alternative to surgical abortions such as vacuum aspiration or dilation and curettage. Medical abortions are more common than surgical abortions in most places around the world.

<span class="mw-page-title-main">SIGA Technologies</span> American pharmaceutical

SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.

<span class="mw-page-title-main">Matthew Kacsmaryk</span> American judge (born 1977)

Matthew Joseph Kacsmaryk is a United States district judge of the U.S. District Court for the Northern District of Texas. He was nominated to the position by President Donald Trump in 2017 and sworn in for the position in 2019.

<span class="mw-page-title-main">Aid Access</span> Abortion services provider

Aid Access is a nonprofit organization that provides access to medication abortion by mail to the United States and worldwide. It describes its work as a harm reduction strategy designed to provide safe access to mifepristone and misoprostol for those able to become pregnant in the United States who may not otherwise have access to abortion or miscarriage management services. People are able to manage their own abortion with remote access to a physician and a help-desk for any questions. The website is available in English, Spanish, and Dutch.

As of 2024, abortion is currently illegal in Indiana. It's only legal in cases involving fatal fetal abnormalities, to preserve the life and physical health of the mother, and in cases of rape or incest up to 10 weeks of pregnancy. Previously abortion in Indiana was legal up to 20 weeks; a near-total ban that was scheduled to take effect on August 1 was placed on hold due to further legal challenges, but is set to take place, after the Indiana Supreme Court denied an appeal by the ACLU, and once it certifies a previous ruling, that an abortion ban doesn't violate the state constitution. In the wake of the 2022 Dobbs Supreme Court ruling, abortion in Indiana remained legal despite Indiana lawmakers voting in favor of a near-total abortion ban on August 5, 2022. Governor Eric Holcomb signed this bill into law the same day. The new law became effective on September 15, 2022. But on September 22, 2022, Special Judge Kelsey B. Hanlon of the Monroe County Circuit Court granted a preliminary injunction against the enforcement of the ban. Her ruling allows the state's previous abortion law, which allows abortions up to 20 weeks after fertilization with exceptions for rape and incest, to remain in effect.

U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine is a pending United States Supreme Court case to challenge the U.S. Food and Drug Administration (FDA)'s approval of mifepristone, a drug frequently used in medical abortion procedures. The plaintiffs, led by the Alliance for Hippocratic Medicine (AHM), argue that the FDA did not properly approve the use of the drug mifepristone for pregnancy termination under Federal Food, Drug, and Cosmetic Act regulations and ask for an injunction to withdraw the drug's approval, thus removing it from the market. AHM's suit followed the Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization in 2022, which reversed Roe v. Wade and asserted there was no constitutional right to abortion at the federal level, leading to conservative states and groups to further restrict abortion access.

References

  1. 1 2 "Corcept Therapeutics Announces Oncology Development Program". corcept.com. Corcept Therapeutics. December 12, 2013. Archived from the original on September 22, 2018. Retrieved September 23, 2018.
  2. 1 2 3 "Discovery & Development". corcept.com. Corcept Therapeutics. 2016. Archived from the original on September 23, 2018. Retrieved September 23, 2018.
  3. 1 2 "Executive Team". corcept.com. Corcept Therapeutics. 2016. Retrieved September 24, 2018.
  4. 1 2 "Corcept Therapeutics Inc (CORT.O)". reuters.com. Reuters. 2018. Retrieved September 23, 2018.
  5. 1 2 Jacobs, Paul (July 10, 2006). "Science critics make issue of financial ties". The Mercury News . Archived from the original on August 29, 2006. Retrieved September 29, 2018.
  6. ↑ "About Corcept". corcept.com. Corcept Therapeutics. 2016. Retrieved September 28, 2018.
  7. ↑ Weintraub, Arlene (June 26, 2008). "Drugmakers and College Labs: Too Cozy?". Bloomberg Businessweek . Archived from the original on May 24, 2011. Retrieved September 28, 2018.
  8. ↑ Viñas, Maria José (August 1, 2008). "Stanford Researcher, Accused of Conflicts, Steps Down as NIH Principal Investigator". The Chronicle of Higher Education . Retrieved September 28, 2018.
  9. ↑ "Clinical and Biological Characteristics of Psychotic Depression". clinicaltrials.gov. U.S. National Library of Medicine. March 14, 2014. Retrieved September 28, 2018.
  10. ↑ "Korlym® selected Brand of the Year by Pharmaceutical Executive". corcept.com. Corcept Therapeutics. 2016. Retrieved September 23, 2018.
  11. ↑ "Products". corcept.com. Corcept Therapeutics. 2016. Retrieved September 23, 2018.
  12. 1 2 Corcept Therapeutics Form 10-K for the fiscal year ended December 31, 2017.
  13. 1 2 3 4 5 6 7 Tribble, Sarah Jane (April 10, 2018). "How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine". khn.org. Kaiser Health News. Retrieved September 24, 2018.
  14. ↑ "Mifepristone". The American Society of Health-System Pharmacists. Archived from the original on December 22, 2015. Retrieved December 19, 2015.
  15. ↑ Corey, E.J. (2012). "Mifepristone". Molecules and Medicine. John Wiley & Sons. ISBN   9781118361733. Archived from the original on 2017-09-08.
  16. ↑ "FDA approval letter for Mifepristone". FDA. September 28, 2000. Archived from the original on November 16, 2001. Retrieved 2006-09-16.
  17. ↑ "Abortion Pill Maker Revealed". CBS News. Oct 13, 2000.
  18. ↑ "Korlym". rxlist.com. RxList. 2018. Retrieved September 23, 2018.
  19. ↑ "Important Safety Information and Indications". korlym.com. Corcept Therapeutics. 2018. Retrieved September 23, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.